1. Mathew M, Verma RS. Humanized immunotoxins a new generation of immunotoxins for targeted cancer therapy. Cancer Sci2009;100:1359-65. doi. 10.1111/j.1349-7006.2009.01192.x

2. Uribe ML, Marrocco I, Yarden Y. EGFR in cancer signaling mechanisms drugs and acquired resistance. Cancers2021;13:2748. doi.10.3390/cancers13112748

3. Li YM, Hall WA. Targeted toxins in brain tumor therapy. Toxins2010;2:2645-62. doi.10.3390/toxins2112645

4. Davies RL, Grosse VA, Kucherlapati R, Bothwell M. Genetic analysis of epidermal growth factor action: assignment of human epidermal growth factor receptor gene to chromosome 7. Proc NatI Acad Sci1980;77:4188-92. doi. 10.1073/pnas.77.7.4188

5. Mckenna N. Challenges in scale up of antibody production companies overcoming obstacles In production process. Genet Eng2001;21:10.

6. Li M, Su ZG, Janson JC. Invitro protein refolding by chromatographic procedures. Prot Expr Pur2004;33:1-10. doi.10.1016/j.pep.2003.08.023

7. Tsumoto K, Shinoki K, Kondo H, Uchikawa M, Juji T, Kumagai I. Highly efficient recovery of functional single chain Fv fragments from inclusion bodies overexpressed in Escherichia coli by controlled introduction of oxidizing reagent application to a human single chain Fv fragment. J Immunol Meth1998;219:119-29. doi.10.1016/s0022-1759(98)00127-6

8. Sinacola JR, Robinson AS. Rapid refolding and polishing of single chain antibodies from Escherichia coli inclusion bodies. Prot Expr Pur2002;26:301-8. doi.10.1016/s1046-5928(02)00538-7

9. Menezes MA, Aires KA, Ozaki CY, Ruiz RM, Pereira MC, Abreu PA, et al. Cloning approach and functional analysis of anti intimin single chain variable fragment. BMC Res Notes2011;4:1. doi.10.1186/1756-0500- -30

10. Zettlmeissl G, Rudolph R, Jaenicke R. Reconstitution of lactic dehydrogenase. Noncovalent aggregation vs. reactivation. 1. Physical properties and kinetics of aggregation. Biochemistry1979;18 :5567-71. doi.10.1021/bi00592a007

11. Singh SM, Panda AK. Solubilization and refolding of bacterial inclusion body proteins. J Biosci Bioeng2005;99:303-10. doi. 10.1263/jbb.99.303

12. Gerami SM, Farajnia S, Mahboudi F, Babaei H. Optimizing refolding condition for recombinant tissue plasminogen activator. Iran J Biotechnol 2011;9:253-9.

13. Goodman M. Market watch sales of biologics to show robust growth through to 2013. Nat Rev Drug Discov2009; 8:837. doi.10.1038/nrd3040

14. Demain AL, Vaishnav P. Production of recombinant proteins by microbes and higher organisms. Biotechnol Adv2009;27:297-306. doi. 10.1016/j.biotechadv.2009.01.008

15. Bhopale G, Nanda R. Recombinant DNA expression products for human therapeutic use. Curr Sci2005;89:614-22.

16. Zhang L, Chou CP, Mooyoung M. Disulfide bond formation and its impact on the biological activity and stability of recombinant therapeutic proteins produced by Escherichia coli expression system. Biotechnol Adv2011;29:923-9. doi.10.1016/j.biotechadv.2011.07.013

17. Walsh G. Biopharmaceuticals: recent approvals and likely directions. Trend Biotechnol2005;23:553-8. doi.10.1016/j.tibtech.2005.07.005

18. Tsumoto K, Ejima D, Kumagai I, Arakawa T. Practical considerations in refolding proteins from inclusion bodies. Prot Exp Pur2003;28:1-8. doi.10.1016/s1046-5928(02)00641-1

19. Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NBM, Hamid M. scFv antibody: principles and clinical application. Clin Dev Immunol2012;2012. doi.10.1155/2012/980250

20. Weisser NE, Hall JC. Applications of single chain variable fragment antibodies in therapeutics and diagnostics. Biotechnol Adv2009;27:502-20. doi.10.1016/j.biotechadv.2009.04.004

21. Baneyx F, Mujacic M. Recombinant protein folding and misfolding in Escherichia coli. Nat Biotechnol2004;22:1399-408. doi.10.1038/nbt1029.

22. Villaverde A, Carrio MM. Protein aggregation in recombinant bacteria biological role of inclusion bodies. Biotechnol let2003;25:1385-95. doi.10.1023/a:1025024104862

23. Yang Z, Zhang L, Zhang Y, Zhang T, Feng Y, Lu X, et al. Highly efficient production of soluble proteins from insoluble inclusion bodies by a two step denaturing and refolding method. PLos One2011;6:22981. doi.10.1371/journal.pone.0022981

24. Oganesyan N, Kim SH, Kim R. On column chemical refolding of proteins. Pharmacogenomics 2004;4:22-5.

25. Goldstein NI, Giorgio NA, Jones ST, Saldanha JW. Humanized anti EGF receptor monoclonal antibody. Patents; 20062:231-6.

26. Sun H, Wu G, Chen Y, Tian Y, Yue Y, Zhang G. Expression production and renaturation of a functional single chain variable antibody fragment against human ICAM1. Braz J. Med Biol Res2014;47:540-7. doi.10.1590/1414-431x20143276

27. Akbari B, Farajnia S, Zarghami N, Mahdieh N, Rahmati M, Khosroshahi SA, et al. Construction expression and activity of a novel immunotoxin comprising a humanized antiepidermal growth factor receptor scFv and modified Pseudomonas aeruginosa exotoxin A. Antican Drug2017;28:263-70. doi. 10.1097/CAD.0000000000000452

28. Akbari B, Farajnia S, Zarghami N, Mahdieh N, Rahmati M, Khosroshahi SA, et al. Design expression and evaluation of a novel humanized single chain antibody against epidermal growth factor receptor. Prot Exp Pur2016;127:8-15. doi.10.1016/j.pep.2016.06.001

29. Buchner J, Rudolph R. Renaturation, purification and characterization of recombinant F ab-fragments produced in Escherichia coli. Biotechnology 1991;9(2):157-62. doi.10.1038/nbt0291-157

30. Kim SH. Expression and purification of recombinant immunotoxin a fusion protein stabilizes a single chain Fv in denaturing condition. Prot Exp Pur2003;27:85-9. doi. 10.1016/s1046-5928(02)00539